#METABOLOMICS WORKBENCH zhaom_20220406_224130 DATATRACK_ID:3180 STUDY_ID:ST002126 ANALYSIS_ID:AN003479
VERSION                          	1
CREATED_ON                       	05-31-2022
#PROJECT
PR:PROJECT_TITLE                 	Amino acid catabolism in hematopoietic cells
PR:PROJECT_SUMMARY               	Hematopoietic stem cells (HSCs) adapt their metabolism to maintenance and
PR:PROJECT_SUMMARY               	proliferation, but the mechanism remains incompletely understood. Here, we have
PR:PROJECT_SUMMARY               	investigated the total levels, uptake and catabolism of amino acid in
PR:PROJECT_SUMMARY               	hematopoietic stem cells, hemopoietic progenitors, and differentiated
PR:PROJECT_SUMMARY               	hematopoietic cells. We have also studied the catabolism of amino acid in
PR:PROJECT_SUMMARY               	hematopoietic stem cells under different conditions, such as homeostasis and
PR:PROJECT_SUMMARY               	proliferation and with drug treatment. Moreover, glycolytic metabolite, NAD+
PR:PROJECT_SUMMARY               	precursor nicotinamide riboside (NR), accelerated AA catabolism to activate GCN2
PR:PROJECT_SUMMARY               	and sustain long-term function of HSCs. Overall, our study uncovers the direct
PR:PROJECT_SUMMARY               	links between metabolic alterations and translation control in HSCs during
PR:PROJECT_SUMMARY               	homeostasis and proliferation.
PR:INSTITUTE                     	Sun Yat-sen University
PR:LAST_NAME                     	Zhao
PR:FIRST_NAME                    	Meng
PR:ADDRESS                       	Zhongshan 2nd Road
PR:EMAIL                         	zhaom38@mail.sysu.edu.cn
PR:PHONE                         	18138799889
PR:DOI                           	http://dx.doi.org/10.21228/M8GD8D
#STUDY
ST:STUDY_TITLE                   	Amino acids and TCA substrates in hematopoietic cells (Part3)
ST:STUDY_SUMMARY                 	This study uses [13C,15N] labeled amino acids to study the amino acid
ST:STUDY_SUMMARY                 	consumption and their catabolism into tricarboxylic acid cycle substrates in
ST:STUDY_SUMMARY                 	hematopoietic stem cells, hemopoietic progenitors, and differentiated
ST:STUDY_SUMMARY                 	hematopoietic cells under different conditions, such as homeostasis and
ST:STUDY_SUMMARY                 	proliferation and with drug treatment.
ST:INSTITUTE                     	Sun Yat-sen University
ST:LAST_NAME                     	Zhao
ST:FIRST_NAME                    	Meng
ST:ADDRESS                       	Zhongshan 2nd Road
ST:EMAIL                         	zhaom38@mail.sysu.edu.cn
ST:PHONE                         	18138799889
ST:SUBMIT_DATE                   	2022-04-06
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-fu-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-fu-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-fu-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_0h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-0h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_0h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-0h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_0h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-0h-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_12h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-12h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_12h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-12h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_12h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-12h-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_6h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-6h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_6h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-6h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_ND_6h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nd-6h-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-ct-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-ct-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	RAW_FILE_NAME=hsc-ct-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_NR_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-ct-nr-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_NR_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-ct-nr-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_Ctrl_NR_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-ct-nr-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-fu-nr-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-fu-nr-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	RAW_FILE_NAME=hsc-fu-nr-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_0h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-0h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_0h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-0h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_0h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-0h-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_12h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-12h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_12h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-12h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_12h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-12h-3.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_6h_1	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-6h-1.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_6h_2	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-6h-2.cdf
SUBJECT_SAMPLE_FACTORS           	-	HSC_5FU_NR_6h_3	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	RAW_FILE_NAME=hsc-fu-nr-6h-3.cdf
#COLLECTION
CO:COLLECTION_SUMMARY            	5×10^5 indicated cells were incubated with 100 µM stable [13C,15N] amino acids
CO:COLLECTION_SUMMARY            	(MSK-A2-US-1.2, Cambridge Isotope Laboratories) for indicated time and
CO:COLLECTION_SUMMARY            	centrifuged at 500 g for 5 min at 4 °C. The pelleted cells were extracted in
CO:COLLECTION_SUMMARY            	500 µl ice-cold Acetonitrile: Isopropyl Alcohol: water (3:3:2 v/v/v) and
CO:COLLECTION_SUMMARY            	aliquoted as three technical replicates. The extracts were vortexed for 5 min at
CO:COLLECTION_SUMMARY            	4 °C and centrifuged at 14,000 g for 2 min at 4 °C. The supernatants were
CO:COLLECTION_SUMMARY            	dried by vacuum spin for subsequent derivatization and stored at -20 ℃.
CO:SAMPLE_TYPE                   	Bone marrow
#TREATMENT
TR:TREATMENT_SUMMARY             	Germ-free C57BL/6J mice were intraperitoneally injected with 10 mg/kg 5FU
TR:TREATMENT_SUMMARY             	(F6627-5G, Sigma-Aldrich) for 14 days, or fed with vehicle or NR (400 mg/kg per
TR:TREATMENT_SUMMARY             	day) (1341-23-7, ziyi-reagent) for consecutive 8 weeks (long-term) or 1 week
TR:TREATMENT_SUMMARY             	(short-term). Hematopoietic cells were stained and sorted from treated mice.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	To get the corresponding derivatives, the dried aliquots were incubated with 20
SP:SAMPLEPREP_SUMMARY            	µL 2% (w/v) methoxyamine hydrochloride (226904, Sigma-Aldrich) in pyridine for
SP:SAMPLEPREP_SUMMARY            	60 min at 37 °C, and silylated by 30 µL of
SP:SAMPLEPREP_SUMMARY            	N-Methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide with 1%
SP:SAMPLEPREP_SUMMARY            	tert-Butyldimethylchlorosilane (TBDMS, 18162-48-6, Regis Technologies) for 30
SP:SAMPLEPREP_SUMMARY            	min at 45 °C. The corresponding derivatives were analyzed by GC-MS using the
SP:SAMPLEPREP_SUMMARY            	Trace 1310 gas chromatograph (Thermo Fisher) with the DB-35ms column (Agilent
SP:SAMPLEPREP_SUMMARY            	Technologies) connected to the Q ExactiveTM GC OrbitrapTM GC-MS/MS system
SP:SAMPLEPREP_SUMMARY            	(Thermo Fisher).
#CHROMATOGRAPHY
CH:INSTRUMENT_NAME               	TRACE 1310
CH:COLUMN_NAME                   	DB-35ms
CH:CHROMATOGRAPHY_TYPE           	GC
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	EI
MS:MS_COMMENTS                   	GC-MS data was acquired on Q-Exactive Orbitrap mass spectrometer (Thermo Fisher)
MS:MS_COMMENTS                   	coupled with Gas Chromatograph system TRACE 1310 (Thermo Fisher).
MS:MS_COMMENTS                   	Chromatographic separation was performed on a DB-35ms column module (30 m length
MS:MS_COMMENTS                   	x 0.25 mm internal diameter, Agilent Technologies). The column temperature was
MS:MS_COMMENTS                   	programmed with an initial temperature of 50 °C for 2 min, then ramped at
MS:MS_COMMENTS                   	10°C/min to 325 °C, and maintained for 5 min. The mass range was set as 50-600
MS:MS_COMMENTS                   	m/z, and the resolution was 60,000. The ion source temperature was 300°C with
MS:MS_COMMENTS                   	the transfer line temperature of 250°C, and the electron energy was 70 eV with
MS:MS_COMMENTS                   	EI source.
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	Peak Area
MS_METABOLITE_DATA_START
Samples	HSC_5FU_1	HSC_5FU_2	HSC_5FU_3	HSC_5FU_ND_0h_1	HSC_5FU_ND_0h_2	HSC_5FU_ND_0h_3	HSC_5FU_ND_12h_1	HSC_5FU_ND_12h_2	HSC_5FU_ND_12h_3	HSC_5FU_ND_6h_1	HSC_5FU_ND_6h_2	HSC_5FU_ND_6h_3	HSC_Ctrl_1	HSC_Ctrl_2	HSC_Ctrl_3	HSC_Ctrl_NR_1	HSC_Ctrl_NR_2	HSC_Ctrl_NR_3	HSC_5FU_NR_1	HSC_5FU_NR_2	HSC_5FU_NR_3	HSC_5FU_NR_0h_1	HSC_5FU_NR_0h_2	HSC_5FU_NR_0h_3	HSC_5FU_NR_12h_1	HSC_5FU_NR_12h_2	HSC_5FU_NR_12h_3	HSC_5FU_NR_6h_1	HSC_5FU_NR_6h_2	HSC_5FU_NR_6h_3
Factors	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).	
[13C_ 15N]Alanine_ 2TBDMS	66700.0000	68400.0000	68400.0000	2910000.0000	2520000.0000	2940000.0000	778000.0000	884000.0000	863000.0000	1600000.0000	1400000.0000	1370000.0000	61300.0000	60400.0000	63200.0000				63000.0000	76000.0000	52000.0000	2530000.0000	3060000.0000	3720000.0000	136000.0000	132000.0000	215000.0000	768000.0000	771000.0000	616000.0000
[13C_ 15N]Aspartic acid_ 3TBDMS	96300.0000	113000.0000	128000.0000	623000.0000	656000.0000	633000.0000	312000.0000	322000.0000	305000.0000	397000.0000	421000.0000	412000.0000	78400.0000	86300.0000	71300.0000				52800.0000	112000.0000	80700.0000	528000.0000	618000.0000	607000.0000	102000.0000	89300.0000	91300.0000	238000.0000	202000.0000	184000.0000
[13C_ 15N]Glutamic acid_ 3TBDMS	74200.0000	71200.0000	73100.0000	512000.0000	527000.0000	567000.0000	215000.0000	206000.0000	194000.0000	352000.0000	345000.0000	394000.0000	32500.0000	31200.0000	35200.0000				73700.0000	58400.0000	67400.0000	537000.0000	584000.0000	574000.0000	35200.0000	41400.0000	35700.0000	183000.0000	156000.0000	204000.0000
[13C_ 15N]Glycine_ 2TBDMS	87200.0000	68500.0000	79900.0000	6870000.0000	7140000.0000	7580000.0000	4290000.0000	4030000.0000	3300000.0000	4960000.0000	4930000.0000	4500000.0000	53400.0000	53500.0000	66900.0000				83000.0000	82000.0000	52400.0000	7740000.0000	6570000.0000	7040000.0000	2430000.0000	2010000.0000	1050000.0000	3640000.0000	2790000.0000	3000000.0000
[13C_ 15N]Histidine_ 3TBDMS	54100.0000	48700.0000	45200.0000	459000.0000	450000.0000	432000.0000	126000.0000	135000.0000	108000.0000	297000.0000	248000.0000	220000.0000	42300.0000	39900.0000	38400.0000				46800.0000	41000.0000	47200.0000	468000.0000	410000.0000	472000.0000	20200.0000	25400.0000	30000.0000	77300.0000	83800.0000	85600.0000
[13C_ 15N]Isoleucine_ 2TBDMS	183000.0000	163000.0000	163000.0000	2770000.0000	2530000.0000	3030000.0000	1320000.0000	1140000.0000	1220000.0000	1850000.0000	1930000.0000	2070000.0000	146000.0000	122000.0000	130000.0000				253000.0000	112000.0000	90000.0000	2530000.0000	3120000.0000	2900000.0000	268000.0000	244000.0000	205000.0000	702000.0000	693000.0000	704000.0000
[13C_ 15N]Leucine_ 2TBDMS	183000.0000	213000.0000	203000.0000	2270000.0000	3080000.0000	2640000.0000	909000.0000	829000.0000	881000.0000	1640000.0000	1740000.0000	1830000.0000	133000.0000	154000.0000	117000.0000				288000.0000	143000.0000	127000.0000	2880000.0000	3430000.0000	3270000.0000	293000.0000	204000.0000	181000.0000	988000.0000	825000.0000	882000.0000
[13C_ 15N]Lysine_ 3TBDMS	74600.0000	84600.0000	78400.0000	1180000.0000	1290000.0000	1200000.0000	480000.0000	478000.0000	456000.0000	746000.0000	755000.0000	826000.0000	58400.0000	51200.0000	56300.0000				104000.0000	71000.0000	118000.0000	1040000.0000	1210000.0000	1180000.0000	42700.0000	31100.0000	50100.0000	258000.0000	297000.0000	284000.0000
[13C_ 15N]Methionine_ 2TBDMS	183000.0000	173000.0000	193000.0000	1520000.0000	1740000.0000	1670000.0000	454000.0000	454000.0000	606000.0000	917000.0000	845000.0000	912000.0000	152000.0000	130000.0000	142000.0000				192000.0000	143000.0000	142000.0000	1620000.0000	1430000.0000	1420000.0000	85700.0000	87600.0000	90400.0000	465000.0000	518000.0000	324000.0000
[13C_ 15N]Phenylalanine_ 2TBDMS	132000.0000	142000.0000	125000.0000	2050000.0000	2040000.0000	2430000.0000	990000.0000	938000.0000	1140000.0000	1330000.0000	1200000.0000	1220000.0000	115000.0000	105000.0000	125000.0000				110000.0000	175000.0000	146000.0000	2000000.0000	2750000.0000	2460000.0000	226000.0000	237000.0000	283000.0000	602000.0000	426000.0000	702000.0000
[13C_ 15N]Proline_ 2TBDMS	143000.0000	132000.0000	133000.0000	1630000.0000	1540000.0000	1480000.0000	489000.0000	402000.0000	437000.0000	759000.0000	758000.0000	707000.0000	78500.0000	86300.0000	88500.0000				143000.0000	175000.0000	152000.0000	1430000.0000	1750000.0000	1520000.0000	125000.0000	96000.0000	113000.0000	406000.0000	381000.0000	401000.0000
[13C_ 15N]Serine_ 3TBDMS	132000.0000	125000.0000	130000.0000	2860000.0000	3140000.0000	3060000.0000	783000.0000	821000.0000	841000.0000	2100000.0000	1940000.0000	2040000.0000	84200.0000	75100.0000	80100.0000				199000.0000	116000.0000	182000.0000	2990000.0000	3160000.0000	2820000.0000	187000.0000	149000.0000	135000.0000	806000.0000	715000.0000	812000.0000
[13C_ 15N]Threonine_ 3TBDMS	17500.0000	18700.0000	20000.0000	684000.0000	702000.0000	678000.0000	283000.0000	299000.0000	253000.0000	412000.0000	388000.0000	396000.0000	12500.0000	14300.0000	14400.0000				19000.0000	26200.0000	20700.0000	690000.0000	662000.0000	707000.0000	86300.0000	75600.0000	74200.0000	252000.0000	210000.0000	223000.0000
[13C_ 15N]Tyrosine_ 3TBDMS	855000.0000	812000.0000	832000.0000	6730000.0000	6950000.0000	6630000.0000	1500000.0000	1720000.0000	1780000.0000	3560000.0000	3050000.0000	2620000.0000	523000.0000	488000.0000	512000.0000				762000.0000	836000.0000	916000.0000	5620000.0000	6360000.0000	7160000.0000	401000.0000	309000.0000	455000.0000	1510000.0000	1680000.0000	1470000.0000
[13C_ 15N]Valine_ 2TBDMS	63200.0000	61300.0000	64300.0000	7380000.0000	6020000.0000	6730000.0000	2510000.0000	2600000.0000	3340000.0000	4620000.0000	4660000.0000	3680000.0000	41200.0000	43200.0000	41300.0000				58000.0000	45000.0000	86000.0000	6580000.0000	7050000.0000	7560000.0000	804000.0000	821000.0000	733000.0000	2170000.0000	1650000.0000	2510000.0000
[13C]Alpha_Ketoglutarate	6380000.0000	6250000.0000	6110000.0000	5130.0000	4850.0000	4760.0000	7580.0000	7260.0000	7370.0000	6030.0000	6430.0000	6900.0000	4010000.0000	4120000.0000	4180000.0000							6240.0000	7240.0000	6930.0000	19500.0000	17300.0000	21600.0000	9690.0000	9530.0000	11500.0000
[13C]Citrate	14400000.0000	14200000.0000	15200000.0000	77000.0000	79500.0000	77000.0000	101000.0000	93000.0000	103000.0000	83700.0000	81100.0000	89300.0000	8530000.0000	7950000.0000	7680000.0000							135000.0000	145000.0000	144000.0000	261000.0000	258000.0000	263000.0000	202000.0000	216000.0000	188000.0000
[13C]Fumatate	62200000.0000	62300000.0000	62300000.0000	90800.0000	98000.0000	93200.0000	120000.0000	113000.0000	125000.0000	119000.0000	119000.0000	116000.0000	41100000.0000	40100000.0000	42000000.0000							139000.0000	145000.0000	147000.0000	345000.0000	340000.0000	348000.0000	256000.0000	235000.0000	261000.0000
[13C]Malate	21600000.0000	24000000.0000	22900000.0000	9790.0000	12700.0000	13200.0000	14800.0000	13200.0000	14000.0000	12400.0000	12800.0000	13400.0000	11700000.0000	9260000.0000	10400000.0000							26000.0000	27200.0000	26800.0000	41300.0000	46000.0000	42700.0000	32400.0000	32200.0000	29300.0000
[13C]Succinate	67300000.0000	61300000.0000	65300000.0000	31700.0000	34400.0000	32100.0000	50400.0000	53200.0000	50700.0000	47700.0000	41600.0000	47500.0000	41700000.0000	40900000.0000	42900000.0000							49100.0000	45300.0000	51300.0000	113000.0000	112000.0000	134000.0000	75700.0000	77300.0000	73100.0000
Alanine_ 2TBDMS	5200000.0000	4720000.0000	5210000.0000										1230000.0000	1590000.0000	1420000.0000	829000.0000	856000.0000	973000.0000	2170000.0000	2150000.0000	2060000.0000									
Alpha_Ketoglutarate	6380000.0000	6250000.0000	6110000.0000										4010000.0000	4120000.0000	4180000.0000	3420000.0000	2900000.0000	3710000.0000	3810000.0000	3730000.0000	4070000.0000									
Aspartic acid_ 3TBDMS	154000000.0000	135000000.0000	137000000.0000										42100000.0000	45200000.0000	47600000.0000	19000000.0000	19500000.0000	24200000.0000	37400000.0000	30800000.0000	42300000.0000									
Citrate	14400000.0000	14200000.0000	15200000.0000										8530000.0000	7950000.0000	7680000.0000	1620000.0000	1360000.0000	1440000.0000	4160000.0000	3990000.0000	3980000.0000									
Fumatate	62200000.0000	62300000.0000	62300000.0000										41100000.0000	40100000.0000	42000000.0000	33400000.0000	36900000.0000	33500000.0000	38300000.0000	41300000.0000	41900000.0000									
Glutamic acid_ 3TBDMS	132000000.0000	142000000.0000	174000000.0000										42100000.0000	40300000.0000	43600000.0000	13600000.0000	13900000.0000	17800000.0000	42600000.0000	42600000.0000	39900000.0000									
Glutamine_ 3TBDMS	1740000.0000	1860000.0000	1520000.0000										386000.0000	412000.0000	432000.0000	238000.0000	279000.0000	202000.0000	582000.0000	469000.0000	483000.0000									
Glycine_ 2TBDMS	542000000.0000	612000000.0000	586000000.0000										253000000.0000	214000000.0000	253000000.0000	106000000.0000	82400000.0000	106000000.0000	126000000.0000	157000000.0000	139000000.0000									
Histidine_ 3TBDMS	284000.0000	320000.0000	218000.0000										52100.0000	41900.0000	52900.0000	24300.0000	24100.0000	29700.0000	37900.0000	40300.0000	39600.0000									
Hydroxyproline_ (E)-_ 3TBDMS	4760000.0000	5200000.0000	5340000.0000										1190000.0000	1390000.0000	1240000.0000	805000.0000	702000.0000	639000.0000	1580000.0000	1460000.0000	1570000.0000									
Isoleucine_ 2TBDMS	15400000.0000	17400000.0000	18400000.0000										5410000.0000	5120000.0000	5340000.0000	2420000.0000	2500000.0000	3240000.0000	3660000.0000	4910000.0000	4820000.0000									
L-Cysteine_ 3TBDMS	3250000.0000	2840000.0000	3100000.0000										686000.0000	854000.0000	774000.0000	32500.0000	31800.0000	35500.0000	65000.0000	68600.0000	76500.0000									
Leucine_ 2TBDMS	41900000.0000	45800000.0000	43900000.0000										12000000.0000	13900000.0000	14100000.0000	4780000.0000	5000000.0000	6230000.0000	7030000.0000	9670000.0000	11700000.0000									
Lysine_ 3TBDMS	15200000.0000	18600000.0000	14400000.0000										4220000.0000	3420000.0000	4180000.0000	2220000.0000	2110000.0000	2810000.0000	4750000.0000	4090000.0000	3970000.0000									
Malate	21600000.0000	24000000.0000	22900000.0000										11700000.0000	9260000.0000	10400000.0000	8150000.0000	8380000.0000	7100000.0000	10100000.0000	11800000.0000	11000000.0000									
Methionine_ 2TBDMS	12300000.0000	14200000.0000	13400000.0000										3520000.0000	3100000.0000	3370000.0000	1040000.0000	1040000.0000	1210000.0000	2580000.0000	2840000.0000	2220000.0000									
Phenylalanine_ 2TBDMS	6520000.0000	4320000.0000	6320000.0000										1860000.0000	2100000.0000	2100000.0000	1210000.0000	1230000.0000	1590000.0000	2770000.0000	2070000.0000	2330000.0000									
Proline_ 2TBDMS	65500000.0000	58200000.0000	87000000.0000										10200000.0000	13200000.0000	12500000.0000	5270000.0000	5160000.0000	7120000.0000	18400000.0000	18700000.0000	16200000.0000									
Serine_ 3TBDMS	52200000.0000	51700000.0000	56000000.0000										18600000.0000	21800000.0000	20900000.0000	7280000.0000	6280000.0000	8750000.0000	14400000.0000	16500000.0000	17900000.0000									
Succinate	67300000.0000	61300000.0000	65300000.0000										41700000.0000	40900000.0000	42900000.0000	31900000.0000	36600000.0000	31700000.0000	35300000.0000	36600000.0000	39800000.0000									
Threonine_ 3TBDMS	8540000.0000	7420000.0000	6230000.0000										2860000.0000	2510000.0000	2150000.0000	1150000.0000	985000.0000	1600000.0000	2380000.0000	2430000.0000	2190000.0000									
Tyrosine_ 3TBDMS	18400000.0000	21600000.0000	21000000.0000										4720000.0000	5820000.0000	6340000.0000	2760000.0000	3000000.0000	3840000.0000	4340000.0000	6530000.0000	6240000.0000									
Valine_ 2TBDMS	52100000.0000	42300000.0000	51200000.0000										11200000.0000	13200000.0000	14200000.0000	5170000.0000	5230000.0000	6950000.0000	8890000.0000	11200000.0000	15900000.0000
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	pubchem_id	inchi_key	kegg_id	other_id	other_id_type	ri	ri_type	moverz_quant	
[13C, 15N]Alanine, 2TBDMS						15.06			
[13C, 15N]Aspartic acid, 3TBDMS						21.49			
[13C, 15N]Glutamic acid, 3TBDMS						22.54			
[13C, 15N]Glycine, 2TBDMS						15.39			
[13C, 15N]Histidine, 3TBDMS						25.11			
[13C, 15N]Isoleucine, 2TBDMS						17.26			
[13C, 15N]Leucine, 2TBDMS						16.91			
[13C, 15N]Lysine, 3TBDMS						23.48			
[13C, 15N]Methionine, 2TBDMS						19.74			
[13C, 15N]Phenylalanine, 2TBDMS						20.92			
[13C, 15N]Proline, 2TBDMS						20.49			
[13C, 15N]Serine, 3TBDMS						19.94			
[13C, 15N]Threonine, 3TBDMS						20.22			
[13C, 15N]Tyrosine, 3TBDMS						25.51			
[13C, 15N]Valine, 2TBDMS						16.46			
[13C]Alpha_Ketoglutarate						21.03			
[13C]Citrate						26.51			
[13C]Fumatate						18.77			
[13C]Malate						22.05			
[13C]Succinate						18.37			
Alanine, 2TBDMS						15.06			
Alpha_Ketoglutarate						21.02			
Aspartic acid, 3TBDMS						21.48			
Citrate						26.51			
Fumatate						18.76			
Glutamic acid, 3TBDMS						22.53			
Glutamine, 3TBDMS						23.81			
Glycine, 2TBDMS						15.38			
Histidine, 3TBDMS						25.10			
Hydroxyproline, (E)-, 3TBDMS						21.77			
Isoleucine, 2TBDMS						17.25			
L-Cysteine, 3TBDMS						21.94			
Leucine, 2TBDMS						16.90			
Lysine, 3TBDMS						23.47			
Malate						22.04			
Methionine, 2TBDMS						19.73			
Phenylalanine, 2TBDMS						20.91			
Proline, 2TBDMS						20.48			
Serine, 3TBDMS						19.93			
Succinate						18.37			
Threonine, 3TBDMS						20.21			
Tyrosine, 3TBDMS						25.50			
Valine, 2TBDMS						16.45			
METABOLITES_END
#END